
CNTX Stock Forecast & Price Target
CNTX Analyst Ratings
Bulls say
Context Therapeutics Inc. is advancing its clinical program for CTIM-76, a promising bispecific antibody targeting CLDN6, which has shown early signs of clinical activity and safety in preliminary data, supporting ongoing trials in multiple solid tumor types. The company’s strong cash position, projected to last into 2027, enables it to navigate through upcoming clinical and regulatory milestones, attracting potential partners and increasing investor interest ahead of traditional efficacy results. A favorable comparison to competitors’ assets in terms of potency and selectivity strengthens the outlook for CTIM-76, with the potential for substantial valuation impact from further clinical developments.
Bears say
Context Therapeutics Inc's financial outlook is negatively impacted by several key factors, including a reported net loss of $9.7 million for Q3 2025, despite a significant reduction in research and development (R&D) expenses from $16.8 million to $8.7 million. Additionally, the company's ability to secure future financing appears precarious, with an estimated need for approximately $250 million by 2041, while only having a cash runway extending into 2027. The presence of various risks related to safety, efficacy, and regulatory concerns further compound the uncertainty surrounding Context's clinical and preclinical programs, potentially undermining investor confidence.
This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.
CNTX Analyst Forecast & Price Prediction
Start investing in CNTX
Order type
Buy in
Order amount
Est. shares
0 shares